申请人:Lilly Industries Limited
公开号:US04983619A1
公开(公告)日:1991-01-08
Compounds of the following formula have pharmaceutical properties: ##STR1## in which X is R'(HO)C.dbd.C(CN)--, R.sup.1 (CO)--CH(CN)-- or ##STR2## R.sup.1 and R.sup.2 are each hydrogen or C.sub.1-6 alkyl, R.sup.3, R.sup.4, R.sup.5 and R.sup.6 are each hydrogen, hydroxy, halogen, nitro, cyano, carboxy, C.sub.1-4 alkyl, C.sub.1-4 alkoxy, C.sub.1-4 alkylthio, halo-substituted C.sub.1-4 alkyl, halo-substituted C.sub.1-4 alkoxy, halo-substituted C.sub.1-4 alkylthio, C.sub.2-5 alkoxycarbonyl, optionally substituted phenyl, optionally substituted phenoxy, R'R"N-- where R' and R" are each hydrogen or C.sub.1-4 alkyl or R'"CONH-- where R'" is C.sub.1-4 alkyl, or a group of the formula --CR.sup.7 R.sup.8 R.sup.9 in which R.sup.7, R.sup.8 and R.sup.9 are each C.sub.1-6 alkyl, halo-substituted C.sub.1-6 alkyl or optionally substituted phenyl, or R.sup.7 and R.sup.8, together with the carbon atom to which they are attached, form a cycloalkyl group containing 3 to 7 carbon atoms, or R.sup.7, R.sup.8 and R.sup.9 together with the carbon atom to which they are attached, form a bicycloalkyl group containing 4 to 9 carbon atoms, and Y is a 5- or 6-membered heterocyclic ring excluding pyrazole; and salts thereof.
以下化合物具有药理特性:##STR1## 其中X为R'(HO)C.dbd.C(CN)--,R.sup.1 (CO)--CH(CN)--或##STR2## R.sup.1和R.sup.2分别为氢或C.sub.1-6烷基,R.sup.3、R.sup.4、R.sup.5和R.sup.6分别为氢、羟基、卤素、硝基、氰基、羧基、C.sub.1-4烷基、C.sub.1-4烷氧基、C.sub.1-4烷硫基、卤素取代的C.sub.1-4烷基、卤素取代的C.sub.1-4烷氧基、卤素取代的C.sub.1-4烷硫基、C.sub.2-5烷氧羰基、可选择取代的苯基、可选择取代的苯氧基、R'R"N--其中R'和R"分别为氢或C.sub.1-4烷基或R'"CONH--其中R'"为C.sub.1-4烷基,或具有以下式--CR.sup.7 R.sup.8 R.sup.9的基团,其中R.sup.7、R.sup.8和R.sup.9分别为C.sub.1-6烷基、卤素取代的C.sub.1-6烷基或可选择取代的苯基,或R.sup.7和R.sup.8与它们连接的碳原子一起形成含有3至7个碳原子的环烷基,或R.sup.7、R.sup.8和R.sup.9与它们连接的碳原子一起形成含有4至9个碳原子的双环烷基,Y为排除吡唑的5-或6-成员杂环环,以及其盐。